Hisky Medical was pleased to participate in the ADA Scientific Sessions, the world’s leading annual gathering for diabetes research and clinical care, held June 5–8 at the Ernest N. Morial Convention Center in New Orleans, USA. At Booth #2226, strategically positioned near the poster exhibition area, the company welcomed strong, steady foot traffic across the four-day event. The Hisky team delivered over 100 complimentary on-site liver assessments using the iLivTouch® Vibration-Controlled Transient Elastography system, demonstrating its fast, non-invasive measurement of liver fibrosis and steatosis to attendees. In total, the team captured more than 130 qualified leads from the U.S., Latin America and other global regions, with over 30 accounts demonstrating strong intent for future collaboration.

Against the conference’s central research priorities—diabetes complication prevention, technology-enabled chronic disease management, and metabolic disease mechanisms—Hisky highlighted the critical role of early MASLD and MASH detection in people with type 2 diabetes, a population where up to 65% develop metabolic dysfunction-associated liver disease. The team engaged in in-depth professional exchanges with clinicians, researchers and industry partners, positioning iLivTouch® as a clinically validated, competitive solution for routine liver risk stratification within diabetes care. Hisky’s U.S. advisors also held productive dialogues with leading pharmaceutical stakeholders to explore joint opportunities in the U.S. market, advancing the integration of non-invasive liver diagnostics into standard metabolic care.